Craft

VistaGen Therapeutics

Stock Price

$3

2024-10-29

Market Capitalization

$82.5 M

2024-10-29

Revenue

$486 K

FY, 2025

VistaGen Therapeutics Summary

Company Summary

Overview
VistaGen Therapeutics is a biopharmaceutical company that develops and commercializes intranasal products. It offers nasal sprays, investigational neuroactive steroids, oral N-methyl-D-aspartate (NMDA) glycine site antagonists, tasteless synthetic pheromones, etc. The company also specializes in mental health support.
Type
Public
Status
Active
Founded
1998
HQ
South San Francisco, CA, US | view all locations
Website
https://www.vistagen.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Shawn K. Singh

    Shawn K. Singh, Chief Executive Officer and Director

  • Jon S. Saxe

    Jon S. Saxe, Chairman of the Board

    • Jerry Gin

      Jerry Gin, Director

      • Ann Cunningham

        Ann Cunningham, Chief Commercial Officer and Director

      LocationsView all

      1 location detected

      • South San Francisco, CA HQ

        United States

        343 Allerton Avenue

      VistaGen Therapeutics Financials

      Summary Financials

      Revenue (Q3, 2026)
      $303.0K
      Net income (Q3, 2026)
      ($18.9M)
      Cash (Q3, 2026)
      $47.4M
      EBIT (Q3, 2026)
      ($19.5M)
      Enterprise value
      $36.6M

      Footer menu